Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia.

Katagiri, Hideaki; Taketsuna, Masanori; Kondo, Shinpei; Kajimoto, Kenta; Aoi, Etsuko; Tanji, Yuka

Katagiri, Hideaki; Taketsuna, Masanori; Kondo, Shinpei; Kajimoto, Kenta; Aoi, Etsuko; Tanji, Yuka.

Afiliação

Katagiri H; Bio-Medicines, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan.
Taketsuna M; Statistical Sciences, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan.
Kondo S; Post Marketing Study Management, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan.
Kajimoto K; Scientific Communications, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan.
Aoi E; Global Patient Safety Japan, Quality and Patient Safety, Eli Lilly Japan K.K., Kobe, Japan.
Tanji Y; Bio-Medicines, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan.

Neuropsychiatr Dis Treat ; 14: 1083-1091, 2018.

Article em En | MEDLINE | ID: mdl-29719399

Palavras-chave

Japan postmarketing surveillance study; PANSS-EC; agitation; rapid-acting intramuscular olanzapine; schizophrenia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Neuropsychiatr Dis Treat Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google